Skip to main content
Signal8
Launch Terminal

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARSHealthcare
+0.88%$74.85
AH$74.85+0.00%vs close
Mkt Cap$3.5B
Float37.55M
O/S46.79M
Vol
$ Vol
RVOL
Inst Own100.6%
SI15.3%
Earnings
Dilution
Tarsus Pharmaceuticals, Inc. logoNASDAQ:TARS$74.85+0.88%
Phase Distribution
13 lead-sponsored trials·3 active·9 completed
Phase 13
Phase 27
Phase 2/31
Phase 31
Phase 41
Status Overview
Recruiting2
Active, not recruiting1
Completed9
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 4
    Completed

    Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

    Lotilaner ophthalmic solution, 0.25%, Vehicle control

    Demodex Blepharitis

    Enrollment
    145
    Start
    Dec 2023
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT06182358
  • Phase 3
    Completed

    Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

    TP-03, TP-03 Vehicle

    Blepharitis

    Enrollment
    412
    Start
    Apr 2021
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT04784091
  • Phase 2/3
    Completed

    Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

    TP-03, 0.25%, TP-03 Vehicle

    Blepharitis

    Enrollment
    421
    Start
    Sep 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04475432
  • Phase 2
    Completed

    A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

    Low Dose TP-05, High Dose TP-05

    Healthy Volunteer

    Enrollment
    30
    Start
    Dec 2022
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05387083
  • Phase 2
    Completed

    Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

    TP-03, TP-03 Vehicle

    Meibomian Gland Dysfunction, Blepharitis +1

    Enrollment
    39
    Start
    Aug 2022
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT05454956
  • Phase 2
    Completed

    Study of TP-04 in Participants With Papulopustular Rosacea

    Lotilaner Gel, 2.0%

    Papulopustular Rosacea

    Enrollment
    37
    Start
    Mar 2023
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05838170
  • Phase 2
    Unknown status

    Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

    Vehicle of TP-03

    Meibomian Gland Dysfunction, Demodex Infestation of Eyelid +2

    Enrollment
    36
    Start
    Aug 2023
    Primary Completion
    Jun 2024est.
    Completion
    Jun 2024est.
    NCT06054217
  • Phase 2
    Enrolling by invitation

    Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

    lotilaner, Vehicle

    Ocular Rosacea

    Enrollment
    155
    Start
    Dec 2025
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT07443202
  • Phase 2
    Active, not recruiting

    A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

    TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose

    Lyme Disease

    Enrollment
    722
    Start
    Mar 2026
    Primary Completion
    Oct 2027est.
    Completion
    Dec 2027est.
    NCT07562087
  • Phase 2
    Recruiting

    A Study to Evaluate the Efficacy and Safety of TP-06 for PCED

    TP-06, Vehicle of TP-06

    Persistent Corneal Epithelial Defect

    Enrollment
    32
    Start
    Apr 2026
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2028est.
    NCT07886268
  • Phase 1
    Completed

    A Pharmacokinetic Study of TP-05 in Healthy Subjects

    TP-05 (lotilaner oral capsules), Placebo

    Healthy

    Enrollment
    67
    Start
    May 2021
    Primary Completion
    Mar 2022
    Completion
    Jul 2022
    NCT05138796
  • Phase 1
    Completed

    A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

    TP-03 (Lotilaner Ophthalmic Solution), 0.25%

    Healthy

    Enrollment
    24
    Start
    Feb 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT05138861
  • Phase 1
    Completed

    Study to Evaluate the Food Effect of TP-05 in Healthy Participants

    TP-05 (lotilaner oral), fasted group, TP-05 (lotilaner oral), high-fat group

    Healthy

    Enrollment
    42
    Start
    Jan 2023
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT05720364
Search ClinicalTrials.gov for “Tarsus Pharmaceuticals”